Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
- 1 June 2010
- journal article
- review article
- Published by Elsevier in Pharmacological Reviews
- Vol. 62 (2) , 305-330
Abstract
Heptahelical G protein-coupled receptors are the most diverse and therapeutically important family of receptors in the human genome. Ligand binding activates heterotrimeric G proteins that transmit intracellular signals by regulating effector enzymes or ion channels. G protein signaling is terminated, in large part, by arrestin binding, which uncouples the receptor and G protein and targets the receptor for internalization. It is clear, however, that heptahelical receptor signaling does not end with desensitization. Arrestins bind a host of catalytically active proteins and serve as ligand-regulated scaffolds that recruit protein and lipid kinase, phosphatase, phosphodiesterase, and ubiquitin ligase activity into the receptor-arrestin complex. Although many of these arrestin-bound effectors serve to modulate G protein signaling, degrading second messengers and regulating endocytosis and trafficking, other signals seem to extend beyond the receptor-arrestin complex to regulate such processes as protein translation and gene transcription. Although these findings have led to a re-envisioning of heptahelical receptor signaling, little is known about the physiological roles of arrestin-dependent signaling. In vivo, the duality of arrestin function makes it difficult to dissociate the consequences of arrestin-dependent desensitization from those that might be ascribed to arrestin-mediated signaling. Nonetheless, recent evidence generated using arrestin knockouts, G protein-uncoupled receptor mutants, and arrestin pathway-selective “biased agonists” is beginning to reveal that arrestin signaling plays important roles in the retina, central nervous system, cardiovascular system, bone remodeling, immune system, and cancer. Understanding the signaling roles of arrestins may foster the development of pathway-selective drugs that exploit these pathways for therapeutic benefit.Keywords
This publication has 226 references indexed in Scilit:
- β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasisProceedings of the National Academy of Sciences, 2009
- Arrestin-3 is essential for the activation of Fyn by the luteinizing hormone receptor (LHR) in MA-10 cells☆Cellular Signalling, 2008
- Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychoticsProceedings of the National Academy of Sciences, 2008
- Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptorsProceedings of the National Academy of Sciences, 2008
- β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cellsProceedings of the National Academy of Sciences, 2008
- Signaling from β1‐ and β2‐adrenergic receptors is defined by differential interactions with PDE4The EMBO Journal, 2008
- Functional specialization of β-arrestin interactions revealed by proteomic analysisProceedings of the National Academy of Sciences, 2007
- β-Arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expressionMolecular Immunology, 2007
- β-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytesProceedings of the National Academy of Sciences, 2006
- Initial sequencing and analysis of the human genomeNature, 2001